Shanghai Vitalgen BioPharma Co., Ltd.
PrivateLast Round
Series C
May 12, 2022
Total Funding Raised
$136.35M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Shanghai Vitalgen BioPharma Co., Ltd. operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series C round in May 2022.
Shanghai Vitalgen BioPharma Co., Ltd. is a biotechnology company that develops transformative gene and cell therapies for hereditary, neurodegenerative, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Vitalgen BioPharma Co., Ltd. Comparables
Compare Shanghai Vitalgen BioPharma Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PackGene Biotech | 83% | |
| Zhejiang Innoforce Pharmaceuticals | 82% | |
| uBriGene Biosciences | 79% |
For institutional investors. Book with your work email.
Shanghai Vitalgen BioPharma Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 12, 2022 | ||||
| Series B | May 17, 2021 | ||||
| Series A | Dec 2, 2019 | ||||
| Angel | Nov 1, 2018 |
For institutional investors. Book with your work email.
Shanghai Vitalgen BioPharma Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDG Capital | Series C |
| Sherpa Healthcare Partners | Series C |
| Kunlun Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Grew 30% quarter-over-quarter, from 10 to 13 employees.
- May 12, 2022
$55.2M round with CDG Capital, Kunlun Capital, and Sherpa Healthcare Partners.
For institutional investors. Book with your work email.
Shanghai Vitalgen BioPharma Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai Vitalgen BioPharma Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai Vitalgen BioPharma Co., Ltd. a public or private company?
Shanghai Vitalgen BioPharma Co., Ltd. is a private company.
What is the current stock price of Shanghai Vitalgen BioPharma Co., Ltd.?
Shanghai Vitalgen BioPharma Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Shanghai Vitalgen BioPharma Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai Vitalgen BioPharma Co., Ltd. worth (valuation)?
Valuation information for Shanghai Vitalgen BioPharma Co., Ltd. is not publicly available.
Can I buy Shanghai Vitalgen BioPharma Co., Ltd. stock?
Shanghai Vitalgen BioPharma Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai Vitalgen BioPharma Co., Ltd.'s last funding round?
Shanghai Vitalgen BioPharma Co., Ltd.'s most recent funding round was Series C on May 12, 2022.
Who are the main investors in Shanghai Vitalgen BioPharma Co., Ltd.?
Key investors in Shanghai Vitalgen BioPharma Co., Ltd. include CDG Capital, Sherpa Healthcare Partners, Kunlun Capital.
Will Shanghai Vitalgen BioPharma Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai Vitalgen BioPharma Co., Ltd..
How can I track Shanghai Vitalgen BioPharma Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai Vitalgen BioPharma Co., Ltd.'s shares on secondary markets.